Skip to main content

Graves Ophthalmopathy

3
Pipeline Programs
5
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
Botulinum Toxin Type APhase 41 trial
Active Trials
NCT01272414Withdrawn0Est. Feb 2012
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
Otelixizumab - low dosePhase 2
Autonomous Therapeutics
1 program
1
RapamycinPhase 11 trial
Active Trials
NCT05532072Unknown140Est. Sep 2023
International Stem Cell
1 program
Intravenous Methylprednisolone + Oral Methotrexate vs Intravenous Methylprednisolone + PlaceboN/A1 trial
Active Trials
NCT00348413Completed80Est. Jul 2008
GSK
GSKLONDON, United Kingdom
1 program
Otelixizumab - low dosePHASE_21 trial
Active Trials
NCT01114503Terminated2Est. Aug 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AbbVieBotulinum Toxin Type A
GSKOtelixizumab - low dose
Autonomous TherapeuticsRapamycin
International Stem CellIntravenous Methylprednisolone + Oral Methotrexate vs Intravenous Methylprednisolone + Placebo

Clinical Trials (4)

Total enrollment: 222 patients across 4 trials

NCT01272414AbbVieBotulinum Toxin Type A

Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction

Start: Jan 2011Est. completion: Feb 20120
Phase 4Withdrawn
NCT01114503GSKOtelixizumab - low dose

A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease

Start: Jul 2010Est. completion: Aug 20122 patients
Phase 2Terminated
NCT05532072Autonomous TherapeuticsRapamycin

Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy.

Start: Sep 2022Est. completion: Sep 2023140 patients
Phase 1Unknown
NCT00348413International Stem CellIntravenous Methylprednisolone + Oral Methotrexate vs Intravenous Methylprednisolone + Placebo

Thyroid Treatment Trial

Start: Jun 2003Est. completion: Jul 200880 patients
N/ACompleted

Related Jobs

Senior Clinical Scientist

Merck & Co.Merck & Co.
USA - Pennsylvania - North Wales (Upper Gwynedd); USA - California - San Diego (Science Park Road); USA - New Jersey - Rahway; USA - Pennsylvania - West Point (Not Applicable)
2w ago
$115K - $181K/yr

Senior Scientist, Study Manager

Merck & Co.Merck & Co.
USA - Pennsylvania - North Wales (Upper Gwynedd); USA - California - San Diego (Science Park Road); USA - New Jersey - Rahway (Not Applicable)
2w ago
$117K - $184K/yr

Senior Clinical Scientist

Verona PharmaVerona Pharma
USA - Pennsylvania - North Wales (Upper Gwynedd); USA - California - San Diego (Science Park Road); USA - New Jersey - Rahway; USA - Pennsylvania - West Point (Not Applicable)
1mo ago
$115K - $181K/yr

Key Account Manager - Thyroid Eye Disease

AmgenAmgen
Malaysia - Kuala Lumpur
1mo ago

Senior Scientist, Study Manager

Verona PharmaVerona Pharma
USA - Pennsylvania - North Wales (Upper Gwynedd)
1mo ago
$117K - $184K/yr

ViiV Data Management and Engineering Manager

GSKGSK
Japan - Tokyo - Akasaka
2mo ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.